Pharmaceuticals Hong Kong

Hong Kong Asthma & COPD Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Hong Kong Asthma & COPD Drugs Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Disease Type, By Route of Administration, By Medication Type, By Distribution Type, By Geography) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034.

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $83.3 Mn Placeholder estimate
Estimate 2025 $87.4 Mn 0.2% of the global market
Projected 2034 $135.6 Mn 55.1% Adds $48.2 Mn over 9 forecast years
CAGR 2025–2034 5.0% Faster than 8% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Hong Kong is 0.16% of the global market.
  • In APAC, the largest is China at $4.43 Bn.
  • Fastest growing: India at 7% a year.
  • Hong Kong ranks 6th of 9 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$48.2 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Asthma & COPD Drugs Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $83.3 Mn — —
2025 (base) $87.4 Mn +$4.2 Mn —
2026 (forecast) $91.8 Mn +$4.4 Mn +5%
2027 (forecast) $96.4 Mn +$4.6 Mn +10.3%
2028 (forecast) $101.2 Mn +$4.8 Mn +15.8%
2029 (forecast) $106.3 Mn +$5.1 Mn +21.6%
2030 (forecast) $111.6 Mn +$5.3 Mn +27.6%
2031 (forecast) $117.2 Mn +$5.6 Mn +34%
2032 (forecast) $123.0 Mn +$5.9 Mn +40.7%
2033 (forecast) $129.2 Mn +$6.2 Mn +47.7%
2034 (forecast) $135.6 Mn +$6.5 Mn +55.1%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong Asthma & COPD Drugs Market Analysis at a glance
Market size, 2025$87.4 Mn placeholder estimate
Forecast, 2034$135.6 Mn placeholder estimate
Growth (CAGR), 2025–20345.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDisease type, rote of administration, medication type, distribution channel and geography (see all)
Key playersGSK PLC, AstraZeneca, Novartis AG, Boehringer Ingelheim GmbH, Merck & Co., Inc. and 1 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials20 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong Asthma & COPD Drugs Market Analysis Executive Summary

Asthma and chronic obstructive pulmonary disease (COPD) are both lung conditions that cause airway inflammation, making breathing difficult. Asthma usually flares up in response to allergens like pollen or mold, or due to physical exertion. In contrast, COPD encompasses several lung diseases, including emphysema and chronic bronchitis. Emphysema involves damage to the lung’s tiny air sacs (alveoli), while chronic bronchitis is characterized by inflammation of the airways (bronchial tubes). Smoking is the primary cause of COPD. Asthma symptoms can vary and may disappear for extended periods, whereas COPD symptoms are persistent and tend to worsen over time, despite treatment.

The global increase in COPD and asthma caused by industrialization, pollution, and change of lifestyles requires improved medical devices and drugs. Technological developments including nebulizers and smart inhalers are enhancing treatment and education, yet high costs, poor reimbursement, and regulatory constraints are a challenge. Increased growth within the market is likely to result from improvements in drug delivery and monitoring services coupled with higher demand in the Asia-Pacific region because of high smoking rates and better health literacy. High costs, reimbursement issues, safety concerns, and environmental impacts may act as threats to growth. Solving these calls for affordable, efficient and environmentally sustainable products and services. Policies and regulatory authorities will continue to shape the market and access to products through reimbursement and value-based care models.

Bar chart: Hong Kong Asthma & COPD Drugs market size, 2024–2034, placeholder estimates. $83.3 Mn in 2024, $87.4 Mn in 2025 and $135.6 Mn in 2034, 5.0% CAGR.
Hong Kong Asthma & COPD Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong Asthma & COPD Drugs Market Dynamics

Market Growth Drivers

A number of people suffering from COPD and asthma is on the rise in the global arena boosted by factors such as urbanization, pollution, and lifestyle changes making it necessary to invest in improved medical equipment and medication. Advancements like complex nebulizers and smart inhalers increase the usage rate and efficacy of treatment, auguring well for the market. Efforts to raise awareness of patients with respiratory conditions are also driving the adoption of COPD treatments and diagnosis of asthma. However, there are still barriers to growth such as high treatment costs, lack of reimbursement, and restrictive regulatory measures leveled against manufacturing companies such as small and medium-sized enterprises. These challenges effectively become the barriers that create the possibility of putting into place the more effective solutions.

Opportunity

The market for COPD and asthma equipment, including smart inhalers and Advanced nebulizers, is expected to grow based on progressing technologies in COPD and asthma drug delivery and monitoring. Global prevalence and incidence of COPD and asthma are rising due to urbanization, pollution, and changes in lifestyles, which are boosting demand for these tools. Smoking rates are on the rise, coupled with improvement in overall healthcare knowledge in regions like Asia-Pacific where market growth is expected to explode from growing incomes. Besides, the steadily increasing need for over-the-counter remedies and long-term management of conditions and disorders together with increased awareness campaigns are some of the factors that are promoting the market’s growth.

Market Restraints

Increased expense concerning the products used in the management of asthma and COPD contributes to poor utilization among those affected, especially in developing countries. This is worsened by limited reimbursement and healthcare resources as has been mentioned earlier. Manufacturing or safety issues that lead to the recall of these items may lead to reduced sales because customers are hesitant to buy these foods. Other non-pharmacological management options and concerns over use of propellants in the devices can also affect demand. Hence, one of the crucial strategies for addressing these issues is the creation of affordable, efficient, and sustainable substitutes.

Competitive Landscape for Asthma & COPD Drugs Market in Hong Kong

Key Players

Recent Developments:

July 2024, Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

July 2025, The first generic equivalent of AstraZeneca's Symbicort, Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, was introduced by Viatris.

October 2021, Glenmark Pharmaceuticals has launched the Tavulus dry powder inhaler (DPI) in Spain for the treatment of chronic obstructive pulmonary disease (COPD)

June 2021, ChiesiFarmaceuticiSpA has begun the PILASTER study to assess the efficacy and safety of two doses of CHF6001 (Tanimilast) as an add-on to maintenance triple therapy in COPD patients.

Mergers and Acquisitions:

2021, AstraZeneca's $39 billion acquisition of Alexion Pharmaceuticals has bolstered its pipeline in rare diseases and immunology, including treatments for asthma and COPD.

Healthcare Policies and Regulatory Landscape for Asthma & COPD Drugs Market in Hong Kong

Asthma & COPD Drugs in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 20 studies on Asthma & COPD Drugs that are recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Governments are coming up with policies and campaigns to discourage smoking and these will have an effect on the COPD and asthma markets due to the disease incidence reduction. Bureaus such as the FDA and EMA play a role in determining the rate of new drugs approval whereby policy changes have the potential to increase the market entry rates as well as new innovative products. Government legislation may include some environmental standards, for example, in respect to propellants used in inhalers. Increased coverage for reimbursement trends and the rise of value-based care can further improve patient access and market growth. However, this pressure on the producers to keep their prices as reasonable as possible might slow growth of the market due to reduced gross and competition.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Asthma & COPD Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Asthma & COPD Drugs in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 18 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Asthma & COPD Drugs market in Hong Kong?
Placeholder estimate: about $87.4 Mn in 2025, rising to about $135.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Asthma & COPD Drugs market in Hong Kong growing?
Placeholder estimate: about 5.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Asthma & COPD Drugs market report cover?
The report splits the market by disease type (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), rote of administration (Inhaled, Oral, Others), medication type (Long-term Asthma Control Medications, Combination Drugs, Quick-Relief Medications, Anticholinergics and more) and distribution channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies).
Who are the key players in the Asthma & COPD Drugs market?
Key players include GSK PLC, AstraZeneca, Novartis AG, Boehringer Ingelheim GmbH, Merck & Co., Inc. and Roche.
What is driving the Asthma & COPD Drugs market?
A number of people suffering from COPD and asthma is on the rise in the global arena boosted by factors such as urbanization, pollution, and lifestyle changes making it necessary to invest in improved medical equipment and medication.
Who regulates Asthma & COPD Drugs in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Asthma & COPD Drugs are running in Hong Kong?
20 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
How much research is published on Asthma & COPD Drugs?
PubMed lists 25,746 papers on Asthma & COPD Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on respiratory

See the topic